Cargando…

Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy

PURPOSE: Bispecific antibodies (BsAbs) have emerged as a leading drug class for cancer therapy and are becoming increasingly of interest for therapeutic applications. As of April 2020, over 123 BsAbs are under clinical evaluation for use in oncology (including the two marketed BsAbs Blinatumomab and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shuyu, van Duijnhoven, Sander M. J., Sijts, Alice J. A. M., van Elsas, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Review – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679314/ https://www.ncbi.nlm.nih.gov/pubmed/32989604 http://dx.doi.org/10.1007/s00432-020-03404-6

Ejemplares similares

Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells
por: Huang, Shuyu, et al.
Publicado: (2022)

Dual Function pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma
por: Bogen, Jan P., et al.
Publicado: (2019)

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies
por: Kerns, S Jordan, et al.
Publicado: (2021)

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
por: Hägerbrand, Karin, et al.
Publicado: (2022)

Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2018)

Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
por: Dougall, William C., et al.
Publicado: (2019)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Bispecific Antibodies and Gene Therapy
por: Nettelbeck, Dirk M.
Publicado: (2011)

Enhanced antigen immunogenicity induced by bispecific antibodies
Publicado: (1990)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)

Dual targeting of the tumor and its associated vasculature using a single bispecific chimeric antigen receptor molecule
por: Byrd, Tiara, et al.
Publicado: (2014)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
por: Schaller, Teilo H, et al.
Publicado: (2020)

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
por: Zhang, Tiancheng, et al.
Publicado: (2023)

Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1
por: Mun, Sung Soo, et al.
Publicado: (2023)

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
por: Waaijer, Stijn JH, et al.
Publicado: (2020)

A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
por: El Zawily, Amr, et al.
Publicado: (2023)

Retraction statement: Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
Publicado: (2022)

Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response
por: Sapski, Sabrina, et al.
Publicado: (2020)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Mouse IgG2a Isotype Therapeutic Antibodies Elicit Superior Tumor Growth Control Compared with mIgG1 or mIgE
por: Vukovic, Natasa, et al.
Publicado: (2023)

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
por: Kubicka, Ewa, et al.
Publicado: (2022)

Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
por: Sun, Yanze, et al.
Publicado: (2023)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
por: Zekri, Latifa, et al.
Publicado: (2020)

Tumor Antigen-Dependent and Tumor Antigen-Independent Activation of Antitumor Activity in T Cells by a Bispecific Antibody-Modified Tumor Vaccine
por: Fournier, Philippe, et al.
Publicado: (2010)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

Bispecific antibodies: design, therapy, perspectives
por: Sedykh, Sergey E, et al.
Publicado: (2018)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Nanocell targeting using engineered bispecific antibodies
por: Taylor, Karin, et al.
Publicado: (2014)

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
por: Dang, Kevin, et al.
Publicado: (2021)

Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification
por: Kim, Hyori, et al.
Publicado: (2013)

Therapeutic Effect of Ansamitocin Targeted to Tumor by a Bispecific Monoclonal Antibody
por: Okamoto, Kayoko, et al.
Publicado: (1992)

Legomedicine—A Versatile Chemo-Enzymatic Approach for the Preparation of Targeted Dual-Labeled Llama Antibody–Nanoparticle Conjugates
por: van Lith, Sanne A. M., et al.
Publicado: (2017)

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
por: Chen, Xin, et al.
Publicado: (2020)

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2021)

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
por: Leclercq-Cohen, Gabrielle, et al.
Publicado: (2023)

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
por: Dheilly, Elie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ln5ma0v8og5hokth6o6spstip3